Bapotulimab
Modify Date: 2024-01-15 12:51:45
Bapotulimab structure
|
Common Name | Bapotulimab | ||
|---|---|---|---|---|
| CAS Number | 2359413-58-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BapotulimabBapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects[1]. |
| Name | Bapotulimab |
|---|
| Description | Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Bapotulimab 阻断 ILDR2 对 T 细胞活化的免疫抑制作用。Bapotulimab 具有小鼠/人交叉反应性，因为 ILDR2 在人和鼠直系同源物的细胞外结构域之间具有 98% 的序列同一性[1]。 Bapotulimab (BAY-1905254；5、25、100 或 500 ng/mL) 在体外促进 T 细胞活化并增强抗原特异性 T 细胞增殖[1]。 |
| In Vivo | Bapotulimab（BAY-1905254；10 mg/kg；腹腔注射；在第 1 天和第 4 天）显示抗原特异性 T 细胞增殖和细胞毒性显着增加[1]。 Animal Model: 8- to 12-week-old CD45.1-expressing C57BL/6 wild-type mice injected with OT-I transgenic T cells[1] Dosage: 10 mg/kg Administration: i.p.; on days 1 and 4 Result: Showed significantly increased antigen-specific T-cell proliferation and cytotoxicity. |
| References |
| No Any Chemical & Physical Properties |